Finally An Osteoporosis Prescription That Will Help Inhibit Bone Loss
- Date: 2008-08-04 - Word Count: 402
Share This!
Amgen NASDAQ: AMGN pharmaceutical company just announced positive performance results for denosumab Pivotal Postmenopausal Osteoporosis Trial.
Trial met primary endpoint of Reducing new vertebral fractures and secondary endpoints of reducing time to first non-vertebral and hip fractures; adverse events similar to placebo. The past president of the National Osteoporosis Foundation Stated, " I am particularly excited about these findings because they indicate that denosumab may offer an important new option for patients."
Denosumab is the premier fully human monoclonal antibody in late stage clinical development that specifically targets RANK Ligand, an essential regulator of osteoclasts the cells that break down bone). Denosumab is being considered for its ability to inhibit all stages of osteoclast activity by a targeted mechanism. Denosumab is being studied for a variety of bone loss conditions including rheumatoid arthritis, postmenopausal osteoporosis, and cancer treatment-induced bone loss in breast cancer and prostate cancer patients| in prostate cancer and breast cancer patients as well as for its potential to delay bone metastases and inhibit and treat bone destruction across many stages of cancer.
Osteoporosis is often referred to as the "silent epidemic", osteoporosis is a global problem illness, which is increasing in dominance as the world population both ages and increases. The World Health Organization (WHO) has recently identified osteoporosis as a priority health issue in addition to other major non-communicable diseases. We are dependent on the pharmaceutical industry to help combat this terrible disease.
According to Amgen the financial burden of osteoporosis is comparable to as the "silent epidemi' to that of other major chronic diseases; for example, in the U.S. the costs associated with osteoporosis-related fractures are equivalent to those of cardiovascular disease and asthma (i)(ii)(iii). It has been reported that osteoporosis results in more hospital bed-days than stroke, myocardial infarction or breast cancer (iv).
Pharmacist-clinical have been developing prescriptions drugs to help patient who experience serious side effects. These products are developed simultaneously the medications that aid in the treatment of the initial illness. The fact that research is available to help predict the potential effects and interactions drugs have with one another is outstanding.
These medicines are prescribed to prevent and treat osteoporosis. A few prescriptions slow the rate of bone loss or increase bone thickness. Even small amounts of new bone growth can reduce the danger of broken bones. It is important that you take calcium and vitamin D, eat well and exercise when you take osteoporosis prescriptions.
Trial met primary endpoint of Reducing new vertebral fractures and secondary endpoints of reducing time to first non-vertebral and hip fractures; adverse events similar to placebo. The past president of the National Osteoporosis Foundation Stated, " I am particularly excited about these findings because they indicate that denosumab may offer an important new option for patients."
Denosumab is the premier fully human monoclonal antibody in late stage clinical development that specifically targets RANK Ligand, an essential regulator of osteoclasts the cells that break down bone). Denosumab is being considered for its ability to inhibit all stages of osteoclast activity by a targeted mechanism. Denosumab is being studied for a variety of bone loss conditions including rheumatoid arthritis, postmenopausal osteoporosis, and cancer treatment-induced bone loss in breast cancer and prostate cancer patients| in prostate cancer and breast cancer patients as well as for its potential to delay bone metastases and inhibit and treat bone destruction across many stages of cancer.
Osteoporosis is often referred to as the "silent epidemic", osteoporosis is a global problem illness, which is increasing in dominance as the world population both ages and increases. The World Health Organization (WHO) has recently identified osteoporosis as a priority health issue in addition to other major non-communicable diseases. We are dependent on the pharmaceutical industry to help combat this terrible disease.
According to Amgen the financial burden of osteoporosis is comparable to as the "silent epidemi' to that of other major chronic diseases; for example, in the U.S. the costs associated with osteoporosis-related fractures are equivalent to those of cardiovascular disease and asthma (i)(ii)(iii). It has been reported that osteoporosis results in more hospital bed-days than stroke, myocardial infarction or breast cancer (iv).
Pharmacist-clinical have been developing prescriptions drugs to help patient who experience serious side effects. These products are developed simultaneously the medications that aid in the treatment of the initial illness. The fact that research is available to help predict the potential effects and interactions drugs have with one another is outstanding.
These medicines are prescribed to prevent and treat osteoporosis. A few prescriptions slow the rate of bone loss or increase bone thickness. Even small amounts of new bone growth can reduce the danger of broken bones. It is important that you take calcium and vitamin D, eat well and exercise when you take osteoporosis prescriptions.
Related Tags: women, prescription, pharmaceutical, pharmacist, clinical pharmacist, pharmacist clinicalhealth
pharmaceutical Your Article Search Directory : Find in Articles
Recent articles in this category:
- Causes Of Leukemia
Leukemia causes are still unknown. In present, medical science isn't able to establish the specific - Information About Leukemia
Leukemia is a disease that is considered to be life-threatening. It requires prompt intervention whe - Complete Information On Chronic Myelogenous Leukemia
Chronic myeloid leukemia (CML), too known as chronic myelogenous leukemia. Chronic myelogenous leuke - Complete Information On Chronic Lymphocytic Leukemia
The chronic lymphocytic leukemia is the type leukemia. The leukemia either the leukemia are the bloo - Use Of Cord Blood To Cure Leukemia
A three-year-old leukemia victim was given a life-saving infusion of her own cord blood, marking the - Mantle Cell Lymphoma-An Indolent Or An Aggressive Disease?
Mantle cell lymphoma is a non-Hodgkin's lymphoma type of cancer and it represents affection of the l - Gleevec Therapy Method For Leukemia
The therapy of chronic myeloid leukemia with Gleevec (Imatinib mesylate) began to be used in patient - Acute Lymphocytic Leukemia in Children
Cancer in any of its forms is known to the society as a condition of adults or elder persons; still - General aspects of Mantle Cell Lymphoma
Mantle cell lymphoma (MCL) takes part to a group of cancers which affect the lymphatic system. This - Diagnosing Lymphoma
Lymphoma is one of the few types of cancer that can develop and grow in the body without an individu
Most viewed articles in this category:
- Monoclonal Antibody - Alternatives for Treating Non-Hodgkin's Lymphoma
Non-Hodgkin's lymphoma or NHL is a serious affection which occurs due to the presence of B cells (B - What Is Lymphoma?
Most folks diagnosed with any type of cancer notice it hugely difficult to agree with their predicam - Diagnosing Lymphoma
Lymphoma is one of the few types of cancer that can develop and grow in the body without an individu - Aspartame and the Increased Risks of Lymphoma Cancer
According to the findings of a recent study conducted by the Cancer Research Center of the European - General aspects of Mantle Cell Lymphoma
Mantle cell lymphoma (MCL) takes part to a group of cancers which affect the lymphatic system. This - The Pluck Factor
Plucky (pluk'e) adj. Brave and spirited; courageous.Have you ever noticed how few people possess rad - Acute Lymphocytic Leukemia in Children
Cancer in any of its forms is known to the society as a condition of adults or elder persons; still - Gleevec Therapy Method For Leukemia
The therapy of chronic myeloid leukemia with Gleevec (Imatinib mesylate) began to be used in patient - Mantle Cell Lymphoma-An Indolent Or An Aggressive Disease?
Mantle cell lymphoma is a non-Hodgkin's lymphoma type of cancer and it represents affection of the l - Use Of Cord Blood To Cure Leukemia
A three-year-old leukemia victim was given a life-saving infusion of her own cord blood, marking the